Sanofi Pasteur, a division of Sanofi Group, announced that the company’s pentavalent combination vaccine intended for the Russian market is manufactured on the production site of NANOLEK, an innovative biopharmaceutical company located in the Kirov region.
The first batches of vaccine packed at the plant in the Kirov region have been certified at the end of 2016 and, since January 2017, they have become available to consumers. In 2017, the batches of pentavalent vaccine that are planned for distribution in Russia will be manufactured at the Nanolek site. It is expected that by 2019 the full cycle of the finished dosage forms production will be achieved at the site.
The pentavalent combination vaccine is manufactured in Russia as part of a joint project between Sanofi Pasteur and NANOLEK on localization of production, which was launched in 2015 with the signing of a cooperation agreement. Since then, Sanofi Pasteur implemented the quality control techniques on its partner’s site in Russia and trained NANOLEK’s specialists in working with the vaccine at the production site in France, which ensures high quality of the vaccine, regardless of where it was manufactured.